The prolactin release inhibiting action of the dopamine receptor agonist metergoline was investigated in 16 patients with metastatic breast cancer associated with hyperprolactinemia. At a daily dose of 12 mg p.o. for 30 days, the drug was highly effective in lowering prolactin levels (day 0: 1076 +/- 171, day 29: 249 +/- 46 mU/l) in these patients. Starting treatment with 4 mg/day, the side effects of the treatment were mild, including dizziness and nausea.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000216020 | DOI Listing |
Publication Analysis
Top Keywords
breast cancer
8
[metergoline hyperprolactinemic
4
hyperprolactinemic breast
4
cancer phase
4
phase study]
4
study] prolactin
4
prolactin release
4
release inhibiting
4
inhibiting action
4
action dopamine
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!